Specialty purchase

Salix Pharmaceuticals Inc. (NASDAQ:SLPX) began the second half as a takeout candidate in the eyes of some buysiders, and its proposed $2.6 billion acquisition of fellow specialty pharma company Santarus Inc. (NASDAQ:SNTS) last week did little to change those beliefs.